Compare Adaptive Biotechnologies Corp (ADPT) vs Union Pacific Corporation (UNP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Union Pacific Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $19.85 (market cap $3.33B), while Union Pacific Corporation trades at $281.27 (market cap $168.09B). The key difference: Union Pacific Corporation is far larger — about 50.5× Adaptive Biotechnologies Corp's market cap, and Union Pacific Corporation pays a 1.95% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | UNP | |
|---|---|---|
Market Cap | $3.33B | $168.09B |
Sector | Health | Industrials |
52-Week High | $22.37 | $283.12 |
52-Week Low | $10.24 | $214.91 |
Enterprise Value | $3.19B | $198.56B |
Dividend Yield | — | 1.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Union Pacific (UNP) trades at $283.12, up 0.31% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported strong Q1 2026 earnings, beating estimates with EPS of $2.93, and maintains robust profitability with a 29.2% net margin. Recent news highlights the ongoing merger process with Norfolk Southern and a class action lawsuit regarding environmental concerns.
Outlook remains positive with a consensus price target of $290.55, indicating potential upside. Key risks include regulatory scrutiny of the merger and legal challenges. The stock's valuation multiples are elevated, but solid cash flow and dividend growth support investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
